Mathai Mammen
CIK 1421050 · EVP, Pharm, R&D · last filed 2024-06-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$25.37M
Companies
4
Total Filings
64
Lifetime Open-Market Net
-$4.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TXG | Director | 180,259 | $46.72 | $8.42M | -$1.74M | 7 | 2024-06-13 |
| JNJ | EVP, Pharm, R&D | 45,300 | $266.78 | $12.09M | $0 | 2 | 2022-02-17 |
| TBPH | SVP, Research & Development | 288,111 | $16.88 | $4.86M | $0 | 10 | 2016-03-17 |
| Innoviva, Inc. (THRX) Delisted | SVP, Research & Early Clin Dev | 334,040 | $4.06 | $1.36M | -$2.96M | 44 | 2014-08-22 |
Recent Filings · Page 4 of 7
64 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-05-02 | Innoviva, Inc. (THRX) Delisted | Sell (S) | −7,000 | -$236.2K | EDGAR |
| 2013-02-22 | Innoviva, Inc. (THRX) Delisted | Mixed | −12,002 | -$265.5K | EDGAR |
| 2013-02-11 | Innoviva, Inc. (THRX) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2013-01-14 | Innoviva, Inc. (THRX) Delisted | Mixed | +14,050 | $45.0K | EDGAR |
| 2012-11-20 | Innoviva, Inc. (THRX) Delisted | Tax (F) | −4,874 | -$102.7K | EDGAR |
| 2012-11-16 | Innoviva, Inc. (THRX) Delisted | Exer (M) | +5,161 | $16.0K | EDGAR |
| 2012-11-06 | Innoviva, Inc. (THRX) Delisted | Sell (S) | −7,000 | -$150.2K | EDGAR |
| 2012-10-17 | Innoviva, Inc. (THRX) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2012-08-22 | Innoviva, Inc. (THRX) Delisted | Tax (F) | −4,644 | -$125.4K | EDGAR |
| 2012-08-15 | Innoviva, Inc. (THRX) Delisted | Sell (S) | −25,000 | -$643.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.